Previous studies revealed that glioma patients with mutant IDH exhibited a more favorable response to current therapy including radiation and chemotherapy, implying the correlation between molecular alterations and prognosis (Cairncross et al., 2014). This evidence concerns the gene IDH1 and glioma.